New Given PillCam cleared in EU

Given Imaging is set to launch its third PillCam product after receiving the CE Mark to market the PillCam COLON in the European Union

By AVI KRAWITZ
October 23, 2006 07:17

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Given Imaging is set to launch its third PillCam product after receiving the CE Mark to market the PillCam COLON in the European Union. The Yokneam-based company said over the weekend it would unveil the product to physicians at the United European Gastroenterology Week in Berlin this week and that it expects to file for US FDA clearance by year end. The capsule was developed as a diagnostic test to visualize the colon and comes equipped with tiny cameras at each end that capture four images a second for up to 10 hours. Each camera, Given said, contains automatic lighting control and captures more than twice the coverage area and depth of field of its flagship PillCam SB capsule which is used to diagnose diseases in the small intestine.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS